Crohn’s disease (CD) is an inflammatory bowel disease (IBD) characterized by chronic inflammation...
- Majority of Crohn’s disease is either mild or moderately severe
- AstraZeneca’s Imfinzi looks to maintenance setting in advanced NSCLC to reverse fortunes
- Why are over half of newly-approved cancer drugs failing to deliver?
- Anacetrapib failure marks the death of the CETP class of cholesterol-lowering therapies
- Huge drug development opportunities in global immuno-oncology area in Asia-Pacific
Majority of Crohn’s disease is either mild or moderately severe
Crohn’s disease (CD) is an inflammatory bowel disease (IBD) characterized by chronic inflammation of the gut.
Social listening: A tactic to tackle anti-vaccine beliefs
The negative perceptions of vaccines that are held by a small proportion of parents—specifically, a view that the potential risks of vaccination far outweigh any associated benefits—can contribute to outbreaks of vaccine-preventable diseases.
AstraZeneca’s Imfinzi looks to maintenance setting in advanced NSCLC to reverse fortunes
Since the disappointment of the Phase III MYSTIC trial failure earlier this year, AstraZeneca has redirected its efforts in non-small cell lung cancer to gaining approval in the second-line and maintenance settings.
Why are over half of newly-approved cancer drugs failing to deliver?
A recent study has found that only 43% of cancer drugs recently approved in Europe allowed patients to live longer, or improved their quality of life.
Anacetrapib failure marks the death of the CETP class of cholesterol-lowering therapies
Merck & Co recently decided not to apply for regulatory approval of anacetrapib, one of the last-standing drugs from the doomed cholesteryl ester transfer protein (CETP) class of cholesterol-lowering therapies.
Huge drug development opportunities in global immuno-oncology area in Asia-Pacific
The global immuno-oncology arena, estimated to be valued more than $33bn, provides a number of opportunities for drug development companies in the Asia Pacific (APAC) region, according to GlobalData’s R&D Visualization Bullseye Chart.
Deals this week: GlycoMimetics, Erytech Pharma, ObsEva
US-based clinical-stage biotechnology company GlycoMimetics Inc plans to raise $100m by issuing shares of its common stock from time to time in a public offering.
Asia-Pacific: the rising region for cancer vaccine clinical trials
An analysis was conducted by GlobalData into the regions with the highest number of cancer vaccine clinical trials initiated between 2007 and 2016.
Industry trials were more frequent than non-industry trials from 2012 – 2016
As part of our series of white papers tracking clinical trials activity around the world, GlobalData recently compiled a summary of clinical trial in Australia.
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.